1,246 results on '"LAM, CAROLYN S.P."'
Search Results
2. Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial
3. Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study
4. Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
5. Dapagliflozin and Timing of Prior Heart Failure Hospitalization: A Patient-Level Meta-Analysis of DAPA-HF and DELIVER
6. Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk
7. Interleukin-6 and Cardiovascular Events in Healthy Adults: MESA
8. Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
9. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial
10. Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial
11. Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy
12. Milvexian vs apixaban for stroke prevention in atrial fibrillation: The LIBREXIA atrial fibrillation trial rationale and design
13. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction
14. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population
15. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial
16. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial
17. Statins and risks of dementia among patients with heart failure: a population-based retrospective cohort study in Hong Kong
18. Differential Associations of A-/B-Type Natriuretic Peptides With Cardiac Structure, Function, and Prognosis in Heart Failure
19. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
20. Effects of Dapagliflozin in Patients in Asia: A Post Hoc Subgroup Analysis From the DELIVER Trial
21. Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced
22. Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity
23. Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort Analysis
24. Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
25. Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction
26. Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF Trial
27. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
28. Asia-Pacific Investigators and Asian Enrollment in Cardiometabolic Trials: Insights From Publications Between 2011 and 2020
29. Clinical Features of Heart Failure With Normal Ejection Fraction: Insights From the ASIAN-HF Registry
30. Changing health related quality of life and outcomes in heart failure by age, sex and subtype
31. The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF
32. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status
33. Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry
34. Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial
35. Operational challenges and mitigation measures during the COVID-19 pandemic–Lessons from DELIVER
36. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial
37. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3
38. Right Ventricular Function and Pulmonary Coupling in Patients With Heart Failure and Preserved Ejection Fraction
39. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
40. Classification of Heart Failure Events by Severity: Insights From the VICTORIA Trial
41. Association Between Diabetes, Chronic Kidney Disease, and Outcomes in People With Heart Failure From Asia
42. Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
43. Fully Automated Artificial Intelligence Assessment of Aortic Stenosis by Echocardiography
44. Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk
45. Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF
46. Patient-Reported Status and Heart Failure Outcomes in Asia by Sex, Ethnicity, and Socioeconomic Status
47. How to Manage Heart Failure With Preserved Ejection Fraction: Practical Guidance for Clinicians
48. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
49. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy
50. Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective Cohort
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.